A Phase 1, Open-Label, Crossover Study to Evaluate the Drug Interaction Between Dolutegravir and Daclatasvir in Healthy Adult Subjects
Latest Information Update: 16 Dec 2023
Price :
$35 *
At a glance
- Drugs Dolutegravir (Primary) ; Daclatasvir
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 08 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Apr 2014 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.
- 28 Mar 2014 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.